Conference call to take place on Friday, August 15 at 8:30 a.m. U.S Eastern TimeHENDERSON, Nev., Aug. 8, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announces that it will host a conference call on Friday, August 15 at 8.30 a.m. U.S. Eastern Time to discuss its financial and operating results for the second quarter of 2025 and to provide a business update. Details of this event can be found below.Event:   VolitionRx Limited Second Quarter 2025 Earnings and Business Updat ...

HENDERSON, Nev., Aug. 4, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that it has entered into definitive agreements for the purchase and sale of (i)  156,250 shares of its common stock to certain directors and executive officers of the Company (collectively, the "Insiders") at an offering price of $0.64 per share, and (ii) 1,734,375 shares of its common stock, together with common stock purchase warrants t ...

Core Insights - VolitionRx Limited has successfully demonstrated the ability to quantify nucleosomes in whole venous blood using a simple lateral flow device, which can provide rapid results in minutes [1] - The study involved 25 hospital patients and showed strong correlation with Volition's established Nu.Q® nucleosome assay, indicating potential for early detection of immune disruptions in conditions like sepsis [1][3] - The technology represents a significant advancement as it allows for quantitative results rather than just positive/negative outcomes, facilitating better clinical decision-making [3] Company Overview - VolitionRx is a multi-national epigenetics company focused on developing blood tests for early disease detection and monitoring, particularly in conditions associated with NETosis, such as sepsis [6][7] - The company aims to improve patient outcomes through earlier detection and monitoring, which can prolong life and enhance quality of life [7] - Volition's research and development activities are primarily based in Belgium, with additional offices in the U.S. and London [8] Technological Innovation - The SUMMIT program is focused on developing a capillary blood-based lateral flow test for early sepsis diagnosis, supported by the Walloon Region [3] - The lateral flow test technology is designed for ease of use, allowing for immediate testing in various settings without the need for specialized equipment [4] - The Nu.Q® nucleosome assay is a chemiluminescent immunoassay that is already available in 27 European countries and is CE marked for disease detection [5] Market Potential - The rapid identification of high-risk patients at the point-of-care could lead to quicker clinical decisions and improved patient outcomes, particularly in critical conditions like sepsis [2] - The technology has the potential to be particularly beneficial in lower-income countries where laboratory infrastructure may be lacking [2]

Company Overview and Strategy - VolitionRx focuses on advancing low-cost, early detection, and treatment monitoring tests in cancer and sepsis[7] - The company's strategy involves licensing its IP to major players, following a low CapEx/low OpEx model similar to its Nu.Q® Vet business[11, 20] - Volition aims to be cash neutral on a full-year basis in 2025, balancing income with expenditure[87] Veterinary Commercial Progress - The Nu.Q® Vet Cancer test is available in over 20 countries[20] - Approximately 120,000 Nu.Q® Vet Cancer tests and test components were sold in 2024[20, 39] - The company has received $23 million in upfront and milestone payments to date, with an additional $5 million milestone payment anticipated in 2025[20] Expansion into Human Diagnostics - Volition is targeting licensing deals in the human sepsis and cancer space in 2025[10] - The company sees a $4 billion opportunity in lung cancer screening, prognostics, and MRD, and a $1 billion+ opportunity in sepsis testing and monitoring[21] - First revenue was recorded for CE-marked product in Q1 2025[85] Financial Performance - Volition recorded approximately $0.25 million in revenue in Q1 2025, a 44% increase over the first quarter of the prior year[87] - Net cash used in operating activities averaged $1.4 million a month, almost 50% lower than the first quarter of 2024[87]

Core Insights - VolitionRx Limited announced the publication of a clinical study indicating that the Nu.Q® H3.1 biomarker can aid in assessing sepsis, organ failure, and subphenotypes in critically ill ICU patients [1][4] - The study involved 1713 patients and demonstrated that H3.1 nucleosomes are biologically specific markers of NETosis, with implications for prognostic enrichment and therapeutic targeting [2][5] - The findings suggest that H3.1 nucleosomes are associated with sepsis and organ dysfunction, highlighting their potential role in treating excessive NETosis in patients [3][4] Company Overview - VolitionRx is a multi-national epigenetics company focused on developing blood tests for early detection and monitoring of diseases, including cancers and conditions related to NETosis [6][7] - The company aims to improve patient outcomes through earlier detection and monitoring, which can enhance both the quality and longevity of life for patients [7][8] - Volition's research and development activities are primarily based in Belgium, with additional operations in the U.S. and London [8]

Core Insights - VolitionRx Limited is presenting its Nu.Q® Vet Cancer Test at the Asian Meeting of Animal Medicine Specialties (AMAMS 2025) in Thailand, highlighting its potential as a diagnostic tool for veterinary oncology [1][2] - The test has shown promise in differentiating between benign and malignant conditions, particularly Canine Chronic Enteropathy and Gastrointestinal Lymphoma, according to Dr. Masahiko Sato [2] - The company aims to enhance awareness and adoption of the Nu.Q® Vet Cancer Test through clinical research and presentations by leading veterinarians [2] Company Overview - Volition is a multi-national epigenetics company focused on advancing the science of epigenetics to improve outcomes for people and animals with life-altering diseases through earlier detection and monitoring [3] - The company is developing cost-effective blood tests for various diseases, including cancers and conditions associated with NETosis, with the goal of prolonging life and improving quality of life for patients [4] - Volition's research and development activities are primarily based in Belgium, with additional facilities in the U.S. and London [5]

VolitionRX (VNRX) Q1 2025 Earnings Call May 16, 2025 08:30 AM ET Company Participants Louise Batchelor Day - Group Chief Marketing & Communications OfficerTerig Hughes - CFOCameron Reynolds - President and Chief Executive Officer Conference Call Participants Ilya Zubkov - Senior Equity Research AnalystSteven Ralston - Director & Senior Analyst Operator Good morning, ladies and gentlemen. Thank you for standing by. Welcome to VolitionRx's Rx Limited First Quarter twenty twenty five Earnings Conference Call. ...

Financial Data and Key Metrics Changes - Total operating expenses for Q1 2025 declined by 35% compared to Q1 2024, reflecting strong cost management across all spending categories [5][6][8] - Net cash used in operating activities was £4.3 million for Q1 2025, down from £8.3 million in Q1 2024, indicating improved cash flow management [6][10] - Revenue for the quarter was approximately $250,000, representing a 44% increase year-on-year, including the first revenue from human product sales [6][7][8] - Cash and cash equivalents at the end of Q1 2025 totaled approximately $2.6 million, down from $3.3 million at the end of 2024 [7] Business Line Data and Key Metrics Changes - The Nu. Q technology is being commercialized in the human diagnostic market, with significant licensing discussions ongoing with over 10 companies [11][12] - The Nu. Q cancer diagnostic pillar is progressing, with two major companies in active negotiations and a pivotal lung cancer screening study in Taiwan enrolling over 100 patients [14][15] - The Nu. Q NETs technology is also advancing, with a total addressable market for testing and monitoring intensive care patients estimated at $1 billion annually [17][18] Market Data and Key Metrics Changes - The combined market value of seven companies in licensing discussions exceeds $600 billion, highlighting the potential reach of the technology [12] - The total addressable market for cancer and sepsis diagnostics is estimated at $25 billion annually, presenting substantial revenue opportunities [12] Company Strategy and Development Direction - The company aims to achieve cash neutrality for the full year 2025, with a focus on reducing expenses and securing multiple licensing agreements in the human diagnostic space [5][10][36] - The strategy includes leveraging existing partnerships and expanding the global reach of the Nu. Q Vet cancer test while automating central labs to enhance revenue growth [24][25][36] - The company is focused on commercializing its technology quickly to make it accessible worldwide, with a mission to save lives and improve outcomes [35][36] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in maintaining low operating costs while focusing on commercialization efforts [41][44] - The company is optimistic about the progress made in licensing discussions and the potential for significant revenue generation from ongoing clinical studies [33][36] Other Important Information - The company recorded its first revenue from a regulated human product in the EU, marking a significant milestone [72] - Discussions are ongoing with several national lung screening programs, indicating strong interest in the company's diagnostic solutions [34] Q&A Session Summary Question: Is the current low level of operating expenses sustainable for the rest of 2025? - Management confirmed that maintaining low costs is a priority and that they have made significant progress in controlling expenses across all categories [41][42][44] Question: Update on the progress of the feline cancer test? - Management reported that pre-analytics work for the feline cancer test has been completed, and clinical data collection is underway [45][48] Question: What is the operational engagement with partners like Texas A&M and IDEXX? - Management indicated that while they know the volume of purchases, detailed sales flow information is typically not shared due to commercial sensitivity [54][55] Question: Will marketing expenses remain flat for the rest of the year? - Management stated that while they plan to spend less overall, there may be fluctuations in spending due to conference attendance and other marketing activities [58][60] Question: When will revenues from the human study contract in Nu. Q Discover be recognized? - Management noted that the clinical study will run over two years, with revenues expected to be spread out over that period [64][65]

Core Insights - VolitionRx Limited is focusing on commercializing its Nu.Q® platform in the human diagnostics market, with ongoing discussions with over ten companies, whose combined market value exceeds $600 billion [2] - The company aims to secure multiple licensing agreements in the human diagnostics space this year, similar to its strategy in the veterinary market [3] - Volition recorded its first revenue from sales of its CE-marked Nu.Q® NETs automated product in Europe in Q1 2025, marking a significant commercial milestone [4] Financial Highlights - Volition reported approximately $0.25 million in revenue for Q1 2025, a 44% increase compared to the same quarter in the previous year [8] - The net cash used in operating activities averaged $1.4 million per month, nearly 50% lower than in Q1 2024 [8] - The company received $4.3 million in funding during Q1 2025, with about $1.8 million from non-dilutive funding [8] - As of March 31, 2025, cash and cash equivalents totaled approximately $2.6 million, down from $3.3 million as of December 31, 2024 [8] - A convertible loan note was finalized post-quarter end, providing $6.25 million in gross proceeds, repayable over 24 months [8] - The goal for 2025 is to achieve cash neutrality, where income matches expenditure on a cash basis [8]

Financial Performance - Total revenues for Q1 2025 were $246,385, a 43.6% increase from $171,535 in Q1 2024[24] - Service revenues increased significantly to $115,476 in Q1 2025 from $2,938 in Q1 2024[24] - Operating loss for Q1 2025 was $5,521,720, improved from a loss of $8,384,504 in Q1 2024[24] - Net loss attributable to VolitionRx stockholders for Q1 2025 was $5,423,759, compared to $8,367,388 in Q1 2024[24] - The net loss for the three months ended March 31, 2025, was $5,476,627, a 35% improvement compared to a net loss of $8,472,005 in the same period in 2024[162] - The company's net loss was $5.5 million, a decrease of approximately $3.0 million compared to a net loss of $8.5 million for the three months ended March 31, 2024[172] Cash and Liquidity - Cash and cash equivalents decreased to $2,600,342 as of March 31, 2025, down from $3,264,429 at the end of 2024[21] - The company experienced a net cash used in operating activities of $4,298,018 in Q1 2025, an improvement from $8,342,384 in Q1 2024[30] - As of March 31, 2025, the company had cash and cash equivalents of $2.6 million and an accumulated deficit of $235.0 million[48] - The company has determined there is substantial doubt about its ability to continue as a going concern without further financing[173] - The company plans to seek additional capital through the sale of debt or equity securities, which may dilute existing stockholders' ownership[175] Expenses and Cost Management - Research and development expenses for Q1 2025 were $2,607,444, down from $4,629,527 in Q1 2024[24] - Total operating expenses reduced to $5.8 million for the three months ended March 31, 2025, down from $8.6 million in the same period in 2024, reflecting a 33% decrease[162][164] - General and administrative expenses decreased to $2.2 million from $2.3 million, a decline of about 2.2% for the three months ended March 31, 2025, compared to the same period in 2024[167] - Sales and marketing expenses decreased to $0.9 million from $1.7 million, a decrease of approximately 46.1% for the three months ended March 31, 2025, compared to the same period in 2024[169] - The company continues to exercise tight cost controls to conserve cash, including directors and employees exchanging part of their fees for RSUs[50] Stock and Financing Activities - The company raised $2,384,654 from issuances of common stock in Q1 2025, compared to $15,733 in Q1 2024[30] - The company raised net proceeds of $2.3 million from the issuance of 4,102,723 shares at an offering price of $0.55 per share in March 2025[67] - In August 2024, the company raised net proceeds of $6.4 million from the sale of 9,170,000 shares and warrants, with a combined offering price of $0.55 per share[68] - The Company entered into a Capital On DemandTM Sales Agreement to sell shares of common stock with an aggregate offering price of up to $7.5 million[128] - The Company entered into a Securities Purchase Agreement with Lind Global Asset Management for $6,250,000 in funding, issuing a Senior Secured Convertible Promissory Note of $7,500,000 and a warrant for 13,020,834 shares at $0.672 per share[150] Assets and Liabilities - Total current liabilities increased to $8,273,099 as of March 31, 2025, compared to $7,790,747 at the end of 2024[21] - The company reported a total stockholders' deficit of $29,026,675 as of March 31, 2025, compared to $26,107,736 at the end of 2024[23] - The total balance for long-term debt payable was $6,394,857, with $1,065,503 due in 2025 and $3,220,798 due in 2028[105] - The total property and equipment as of March 31, 2025, was $9.76 million, with a net value of $4.35 million after accumulated depreciation[55] Research and Development - The company launched the Nu.Q® Vet Cancer Test in the UK and Ireland in November 2023 and in Japan in July 2024, expanding its market presence[148][149] - The company received a $10 million upfront payment from Heska for exclusive rights to sell the Nu.Q® Vet Cancer Test for companion animals, with potential additional milestone payments[144] - The number of full-time equivalent personnel in the research and development division decreased by 14 to 52 compared to the prior year period[165] Internal Controls and Compliance - The company identified a material weakness in its internal controls over financial reporting and is actively working on remediation plans[187] - The company has no known legal proceedings that it believes will have a material adverse effect on its financial position[115]